AMNIOX Medical wins first agreement for regenerative medicine products
ATLANTA – (COMMERCIAL THREAD) – AMNIOX Medical, Inc., a TissueTech, Inc. company, has secured a group purchase agreement for regenerative skin graft products with Premier. Effective January 1, 2018, the new agreement allows Premier members, at their discretion, to take advantage of special terms pre-negotiated by Premier for AMNIOX Medical’s full portfolio of wound and surgical solutions, which are known as respective NEOX name.®
and CLARIX® brand names.
“We are thrilled to partner with an organization that shares our vision of empowering physicians and their healthcare systems to improve patient outcomes while reducing costs,” said Tom Dugan, CEO of AMNIOX Medical . “Premier members represent major medical centers and institutions across the United States. This alliance with this network reflects our growing presence offering added value in regenerative and restorative medicine. ”
AMNIOX Medical is the leading supplier of an allogeneic human tissue transplant consisting of umbilical cord and amniotic membrane. Biological components of the tissue have been shown to have regenerative properties that may provide healing benefits to patients with many medical conditions. AMNIOX Medical uses its proprietary CRYOTEK™
method, cryopreservation technology proven to preserve the innate biological and structural properties of the matrix, which can then be transplanted into adult wounds and surgical environments.
Premier is a leading healthcare improvement company, bringing together an alliance of approximately 3,900 US hospitals and 150,000 other providers to transform healthcare. With integrated data and analytics, collaborations, supply chain solutions, and consulting and other services, Premier enables better care and better outcomes at lower cost.
About Amniox Medical, Inc.
Founded in 2011 to serve the orthopedics and wound care markets, AMNIOX Medical is dedicated to the development and commercialization of regenerative therapies processed from the umbilical cord and amniotic membrane using its proprietary CRYOTEK technology. AMNIOX Medical obtains its tissues by elective donation after a healthy live birth by Caesarean section. Thorough donor screening is carried out to ensure the safety of its products. For more information, please visit http://www.amnioxmedical.com
About TissueTech, Inc.
TissueTech, Inc., the parent company of AMNIOX Medical, Inc. and Bio-Tissue, Inc., has pioneered the development and clinical application of regenerative amniotic tissue products. AMNIOX Medical develops and markets products intended for the musculoskeletal and wound care markets; Bio-Tissue develops and markets products for the ophthalmology and optometry markets. The National Institutes of Health (NIH) have supported TissueTech’s research with more than 30 continuous years of research grants. Since the company’s inception, clinicians have performed more than 300,000 human implants of the company’s products and published more than 300 peer-reviewed studies supporting its technology platform. The company’s first product, AmnioGraft®, is the only tissue graft designated by the FDA as a homolog to promote healing of ophthalmic wounds while removing scarring and inflammation.